Gastroenteropancreatic neuroendocrine tumors. Where are we now?

Cancer and Metastasis Reviews

Volumn 30, Issue SUPPL. 1, 2011, Pages 1-1

  Castellano, Daniel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; SUNITINIB;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; EDITORIAL; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL;

EID: 79952063685     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9296-x     Document Type: Editorial

References (1)

1. JC Yao M Hassan A Phan C Dagohoy C Leary JE Mares, et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States Journal of Clinical Oncology 26 18 3063 72 18565894 10.1200/JCO.2007.15.4377